Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436615 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum
A Phase 2 study, sponsored by Novan.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT03436615: Completed Phase 2 study, sponsored by Novan.
NCT03436615 is a Phase 2 study that has completed, run by Novan. The registered enrollment target is 256 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03436615, a Phase 2 study, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
Primary Outcome
Percent (proportion) of subjects with complete clearance of all treatable MC at Week 12. This was measured by dividing the number of subjects who showed complete clearance by the number in that treatment group (this represents our primary outcome variable).
Interventions
- DRUG Placebo
- DRUG SB206 4%
- DRUG SB206 8%
- DRUG SB206 12%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2018-11-03 |
| Phase | Phase 2 |
What the finished NCT03436615 record still lists
NCT03436615 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03436615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03436615 about?
NCT03436615 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum". This is a phase 2 multi-center, randomized, double-blind, vehicle-controlled ascending dose study to be conducted in non-immunocompromised subjects with molluscum contagiosum.
What is the current status of trial NCT03436615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2018-01-24. Estimated completion is 2018-11-03.
What interventions are being tested in trial NCT03436615?
The interventions under investigation include: Placebo (DRUG), SB206 4% (DRUG), SB206 8% (DRUG), SB206 12% (DRUG).
Who is sponsoring clinical trial NCT03436615?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03436615's enrollment target sits among peer trials
256 215th of 2000 higher than 1,783 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI